CAMBRIDGE, Mass.--(BUSINESS WIRE)--Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus ...
Anti-herpetic agents reduce recurrence of herpes simplex-2 (HSV-2) symptoms but do not completely block subclinical shedding of virus, even at high doses, researchers reported. In three complementary ...
An investigational drug with a novel mechanism of action reduced the rate of viral shedding in patients with genital herpes simplex virus-2 (HSV-2) infection, researchers reported. In a small, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results